BRCA1 and ovarian carcinoma: Phase I study dose escalation study for olaparib. 15 BRCA-related (14 BRCA1 and 1 BRCA2) chemotherapy refractory ovarian cancer patients were evaluable for treatment efficacy; 8 (53%) OR and 1 (7%) SD were observed. No responses in BRCA-mutation-negative cases included in the study.